Christina Johnson to Antineoplastic Agents
This is a "connection" page, showing publications Christina Johnson has written about Antineoplastic Agents.
Connection Strength
0.514
-
Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. J Urol. 2009 Sep; 182(3):1178-85.
Score: 0.098
-
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol. 2009 Aug; 76(2):342-55.
Score: 0.097
-
Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer Biol Ther. 2009 Jan; 8(1):81-3.
Score: 0.095
-
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther. 2003 May-Jun; 2(3):283-90.
Score: 0.064
-
Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 2002 Sep-Oct; 1(5):520-7.
Score: 0.061
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.058
-
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007 Mar; 14(3):327-34.
Score: 0.021
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.020